Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.

Use of SGLT2i increased 3-fold over 2 years. Although this indicates a more rapid translation of trials results and guidelines into clinical practice compared to previous HF drugs, further efforts are advocated to complete the implementation process while avoiding inequities across different patients' subgroups and discontinuations. This article is protected by copyright. All rights reserved.